ASX:RNO

Rhinomed Stock Forecast, Price & News

Add

Compare

Today's Range N/A

50-Day Range N/A

52-Week Range N/A

Volume452,773 shs

Average VolumeN/A

Market CapitalizationN/A

P/E RatioN/A

Dividend YieldN/A

BetaN/A

Receive RNO News and Ratings via Email

Sign-up to receive the latest news and ratings for Rhinomed and its competitors with MarketBeat's FREE daily newsletter.

About Rhinomed

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It identifies, acquires, and commercializes nasal stent delivery technologies. The company's product portfolio includes Turbine for enhanced breathing in sports; Mute, an anti-snoring device; and Pronto for nasal congestion and sleep disturbance issues. It also engages in developing applications for the delivery of medical cannabis and conditions, including anxiety, pain, allergies, nausea, anxiety, and coughs and colds; and nasal swab to test the presence of upper respiratory tract diseases, including influenza, and coronavirus strains. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is based in Richmond, Australia.

Ethics Approval Granted for Clinical Trial of World's First Nasal Swab Designed Specifically for Children
September 7, 2021 | finance.yahoo.com

We're Not Very Worried About Rhinomed's (ASX:RNO) Cash Burn Rate
August 25, 2021 | finance.yahoo.com

Rhinomed, Zelira And Alcanna Among Top Cannabis Stock Movers On July 12, 2021
July 13, 2021 | finance.yahoo.com

The Non-Executive Director of Rhinomed Limited (ASX:RNO), John McBain, Just Bought 1.2% More Shares
June 25, 2021 | finance.yahoo.com

Have Insiders Been Buying Rhinomed Limited (ASX:RNO) Shares?
May 20, 2021 | finance.yahoo.com

Does Rhinomed's (ASX:RNO) CEO Salary Compare Well With Industry Peers?
February 18, 2021 | finance.yahoo.com

We Think Rhinomed (ASX:RNO) Needs To Drive Business Growth Carefully
December 21, 2020 | finance.yahoo.com

Rhinomed Ltd to Webcast Live at VirtualInvestorConferences.com December 3rd
December 2, 2020 | finance.yahoo.com

Have Insiders Been Buying Rhinomed Limited (ASX:RNO) Shares This Year?
October 21, 2020 | finance.yahoo.com

Should You Worry About Rhinomed Limited's (ASX:RNO) CEO Pay Cheque?
October 21, 2020 | finance.yahoo.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange ASX
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolASX:RNO
Previous Symbol
CUSIPN/A
CIKN/A
Webwww.rhinomed.com.au
Phone+61-3-84160900
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual Sales$4.65 million
Price / Sales0.00
Cash FlowN/A
Price / Cash Flow3.48
Book ValueA$0.02 per share
Price / BookN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Outstanding SharesN/A
Market CapN/A
Next Earnings DateN/A
OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.27 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for Rhinomed.

4.7 Community Rank

Outperform Votes
Rhinomed has received 49 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Rhinomed has received 22 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Rhinomed has received 69.01% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Rhinomed and other stocks. Vote “Outperform” if you believe RNO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe RNO will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Rhinomed does not currently pay a dividend.
Dividend Growth
Rhinomed does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Rhinomed insiders have bought more of their company's stock than they have sold. Specifically, they have bought A$153,017.00 in company stock and sold A$0.00 in company stock.

0.0 Earnings and Valuation

See Top Rated MarketRank™ Stocks Here

Rhinomed (ASX:RNO) Frequently Asked Questions

What stocks does MarketBeat like better than Rhinomed?

Wall Street analysts have given Rhinomed a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Rhinomed wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

How were Rhinomed's earnings last quarter?

Rhinomed Limited (ASX:RNO) released its quarterly earnings data on Thursday, February, 28th. The company reported ($0.02) EPS for the quarter.
View Rhinomed's earnings history.

Who are Rhinomed's key executives?

Rhinomed's management team includes the following people:

Mr. Michael Johnson, CEO, MD & Exec. Director
Mr. Sean Slattery, CFO & Company Sec.

Who are some of Rhinomed's key competitors?

Some companies that are related to Rhinomed include (TNGN) (TNGN), 3SBio (TRSBF), 45525 (CUR.TO) (CUR), Abattis Bioceuticals (ATTBF), Abzena (ABZA), Acrux (ACR), Actinogen Medical (ACW), AdAlta (1AD), Admedus (AHZ), Algernon Pharmaceuticals (AGNPF), Almirall (LBTSF), Amarantus BioScience (AMBS), Amplia Therapeutics (ATX), Anatara Lifesciences (ANR) and Annovis Bio (ANVS).
View all of RNO's competitors.

What is Rhinomed's stock symbol?

Rhinomed trades on the ASX under the ticker symbol "RNO."

How much money does Rhinomed make?

Rhinomed has a market capitalization of $0.00 and generates $4.65 million in revenue each year.

What is Rhinomed's official website?

The official website for Rhinomed is www.rhinomed.com.au.

Where are Rhinomed's headquarters?

Rhinomed is headquartered at 97 Green St, RICHMOND, VIC 3121, Australia.

How can I contact Rhinomed?

Rhinomed's mailing address is 97 Green St, RICHMOND, VIC 3121, Australia. The company can be reached via phone at +61-3-84160900.

This page was last updated on 9/20/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.